PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.29
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.11. Howard Marks would check for debt covenant compliance and refinancing risks.
0.77
Very conservative net debt at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.92. Philip Fisher would suggest checking if this conservatism supports R&D and growth investments.
-1.23
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
5.43
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
42.36%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.95%. Michael Burry would check for aggressive accounting and hidden risks.